Treatment of multiple sclerosis (MS) patients with rituximab leads to lower-than-reported mortality rates, according to a large real-world study in the U.S. and Sweden. The findings also revealed no ... Read more
Multiple sclerosis patients whose first treatment is Genentech’s Rituxan (rituximab) stay on it longer than other disease-modifying drugs that patients start with, a Swedish study reports.
When they stop taking Rituxan, ... Read more
In a recent talk, titled “Income and cognitive impairment among multiple sclerosis patients,” scientists investigated how cognitive impairment impacts the life of patients with multiple sclerosis (MS), and reported significant ... Read more
Mabthera (rituximab), a widely approved drug for treating lymphoma and/or rheumatoid arthritis, is highly effective in treating multiple sclerosis (MS), researchers reported in an observational study in Sweden, where ... Read more
Pin It on Pinterest